Abstract:Objective: The aim: To determine the diagnostic value of non-invasive methods of GERD diagnosis based on questionnaire data and a diagnostic test with a proton pump inhibitor (PPI) with Rabeprazole in patients with coronary heart disease (CHD). Patients and methods: Materials and methods: 90 patients were under observation, namely, 68 patients with coronary heart disease with concomitant essential arterial hyperten¬sion (EAH), 6 patients with coronary artery disease + arrhythmias, and 18 - others diseases. All patients were surveyed according to the GerdQ questionnaire, followed by PPI testing with Rabeprazole, and body mass index (BMI) was calculated for all the patients. A BMI of 18.5-24.9 kg/m2 was considered as normal body weight, and a BMI > 24.9 kg/m2 was considered overweight. Results: Results: Based on the results of the questionnaire, it was established that the most common complaints typical for GERD were noted by patients with CHD in combination with EAH. There were 48 of such patients and, depending on BMI, they were divided into 2 groups: 1st group (n=14) - patients with CHD+EAH+GERD with normal body weight and 2nd group (n=34) - overweight patients with CHD+EAH+GERD. In patients of group 1, typical symptoms of GERD prevailed (in 71.4% of patients), and in patients group 2, the distribution of typical and extra-esophageal symptoms did not differ significantly (52.9% vs. 47.1%). Among the extraesophageal manifestations, pain behind the sternum (in the projection of the esophagus) was significantly more often recorded in patients of group 1, and rhythm disturbances in patients of group 2 (43.8% and 75.0% of patients, respectively, p<0.05). The results of the GerdQ questionnaire showed a direct relationship between GERD, body weight and symptom score. Patients with GERD+normal body weight had a mean score of 6 for classic gastroesophageal reflux symptoms, while patients with GERD+increased body weight had a mean score of 7. The sensitivity of the questionnaire was 78.7%, and the specificity - 92.9%. According to the PPI test, in the 1st and 2nd groups, already in the first three days, 28.5% and 23.5% of patients noted the disappearance of heartburn and after 10 days - 85.7% and 64.7%, respectively. Over the entire period, that is, after 14 days of observation, 85.7% of patients in the 1st group and 73.5% in the 2nd group noted improvement. Conclusion: Conclusions: It has been established that questionnaires based on the GerdQ questionnaire followed by a PPI test with Rabeprazole in patients with coronary heart disease combined with essential arterial hypertension have a high diagnostic value and can be used for early diagnosis and effective treatment of GERD.

Is Proton Pump Inhibitor Testing an Effective Approach to Diagnose Gastroesophageal Reflux Disease in Patients with Noncardiac Chest Pain

[Noncardiac Chest Pain and Gastroesophageal Reflux in Children].

To investigate the relationship between noncardiac chest pain and acid reflux in the aged

Multicenter Comparative Study on the Value of Gastroesophageal Reflux Disease Questionnaire and Proton Pump Inhibitors Test in Diagnosis of Gastroesophageal Reflux Disease

Accuracy of diagnosing gastroesophageal reflux disease by GerdQ, esophageal impedance monitoring and histology.

Validation in China of a Non-Invasive Salivary Pepsin Biomarker Containing Two Unique Human Pepsin Monoclonal Antibodies to Diagnose Gastroesophageal Reflux Disease

The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis

NON-INVASIVE METHODS OF DIAGNOSTICS OF GASTRO-ESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH ISCHEMIC HEART DISEASE

Analysis of 36 Cases of Refractory Gastroesophageal Reflux Disease with Impedance-pH Monitoring

Esophageal chest pain resembles heartburn in reflux metrics and response to proton pump inhibitor therapy

Efficacy of endoscopic radiofrequency ablation for proton pump inhibitor‐dependent gastroesophageal reflux disease: Multicenter prospective cohort study

Empirical Treatment of Outpatients with Gastroesophageal Reflux Disease with Proton Pump Inhibitors: A Survey of Chinese Patients (the ENLIGHT Study)

Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy

The Role of Salivary Pepsin in the Diagnosis of Gastroesophageal Reflux Disease (GERD) Evaluated Using High-Resolution Manometry and 24-Hour Multichannel Intraluminal Impedance-pH Monitoring

Diagnosis of Symptomatic Gastroesophageal Reflux Disease

Effects of Proton-Pump Inhibitors on Functional Dyspepsia: A Meta-analysis of Randomized Placebo-Controlled Trials

The Controversy of Pepsinogen A/Pepsin A in Detecting Extra-Gastroesophageal Reflux

Is Noncardiac Chest Pain Truly Noncardiac?

The Diagnostic Significance of Coapplying a Rabeprazole Test with the SF-36 for Gastroesophageal Reflux Disease.

Diagnostic value of the pepsin concentration in saliva and induced sputum for gastroesophageal reflux-induced chronic cough: a prospective clinical study

Risk Factors for Gastroesophageal Reflux Disease, Reflux Esophagitis and Non-Erosive Reflux Disease among Chinese Patients Undergoing Upper Gastrointestinal Endoscopic Examination